Invention Grant
- Patent Title: Biomarker for measurement of response and prognosis of triple-negative breast cancer to anticancer agent
-
Application No.: US16494557Application Date: 2018-03-08
-
Publication No.: US11339446B2Publication Date: 2022-05-24
- Inventor: Wonshik Han , Dong-Young Noh , Han-Byoel Lee , Eun-Kyu Kim , Ae-Kyung Park , Hyeong-Gon Moon
- Applicant: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION , INDUSTRY-ACADEMIC COOPERATION FOUNDATION OF SUNCHON NATIONAL UNIVERSITY , SEOUL NATIONAL UNIVERSITY HOSPITAL
- Applicant Address: KR Seoul; KR Suncheon-si; KR Seoul
- Assignee: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION,INDUSTRY-ACADEMIC COOPERATION FOUNDATION OF SUNCHON NATIONAL UNIVERSITY,SEOUL NATIONAL UNIVERSITY HOSPITAL
- Current Assignee: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION,INDUSTRY-ACADEMIC COOPERATION FOUNDATION OF SUNCHON NATIONAL UNIVERSITY,SEOUL NATIONAL UNIVERSITY HOSPITAL
- Current Assignee Address: KR Seoul; KR Suncheon-si; KR Seoul
- Agency: Kilpatrick Townsend & Stockton LLP
- Priority: KR10-2017-0032929 20170316
- International Application: PCT/KR2018/002755 WO 20180308
- International Announcement: WO2018/169251 WO 20180920
- Main IPC: C12Q1/6886
- IPC: C12Q1/6886
Abstract:
The present disclosure discloses a biomarker capable of predicting the therapeutic response to anticancer agents and prognosis of triple-negative breast cancer patients, and the use thereof. A biomarker according to the present disclosure allows the provision of optimized personal therapeutic methods through correct personalized treatment, contributing to the quality and prolongation of life of patients.
Public/Granted literature
- US20200087733A1 BIOMARKER FOR MEASUREMENT OF RESPONSE AND PROGNOSIS OF TRIPLE-NEGATIVE BREAST CANCER TO ANTICANCER AGENT Public/Granted day:2020-03-19
Information query
IPC分类:
